Lei Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lei Shi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Jun-Xiang Li
Gastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China
1 shared publicationLi-Juan Liu
Gastroenterology Department of Traditional Chinese Medicine, China-Japan Friendship Hospital, Beijing, 100029, China
1 shared publicationPang-Hua Ding
Gastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China
1 shared publication- Tangyou Mao
Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China
1 shared publication - Yi Guo
Gastroenterology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 5, Haiyuncang Hutong, Beijing 100700, China
1 shared publication - Yun-Liang Wang
Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 7370891
Gegen Qinlian Decoction Attenuates High‐Fat Diet‐Induced Steatohepatitis in Rats via Gut Microbiota
Gut microbiota play an important role in modulating energy contribution, metabolism, and inflammation, and disruption of the microbiome population is closely associated with chronic metabolic diseases, such as nonalcoholic fatty liver disease (NAFLD). Gegen Qinlian decoction (GGQLD), a well‐known traditional Chinese herbal medicine (CHM), was previously found to regulate lipid metabolism and attenuate inflammation during NAFLD pathogenesis. However, the underlying mechanism of this process, as well as how the gut microbiome is involved, remains largely unknown. In this study, we investigated the effect of varying doses of GGQLD on the total amount and distribution of gut bacteria in rats fed a high‐fat diet (HFD) for 8 weeks. Our analysis indicates that Oscillibacter and Ruminococcaceae_g_unclassified are the dominant families in the HFD group. Further, HFD‐dependent differences at the phylum, class, and genus levels appear to lead to dysbiosis, characterized by an increase in the Firmicutes/Bacteroidetes ratio and a dramatic increase in the Oscillibacter genus compared to the control group. Treatment with GGQLD, especially the GGQLL dose, improved these HFD‐induced changes in intestinal flora, leading to increased levels of Firmicutes, Clostridia, Lactobacillus, bacilli, and Erysipelotrichales that were similar to the controls. Taken together, our data highlight the efficacy of GGQLD in treating NAFLD and support its clinical use as a treatment for NAFLD/NASH patients.
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 7370891
Open AccessGegen Qinlian Decoction Attenuates High‐Fat Diet‐Induced Steatohepatitis in Rats via Gut Microbiota
Gut microbiota play an important role in modulating energy contribution, metabolism, and inflammation, and disruption of the microbiome population is closely associated with chronic metabolic diseases, such as nonalcoholic fatty liver disease (NAFLD). Gegen Qinlian decoction (GGQLD), a well‐known traditional Chinese herbal medicine (CHM), was previously found to regulate lipid metabolism and attenuate inflammation during NAFLD pathogenesis. However, the underlying mechanism of this process, as well as how the gut microbiome is involved, remains largely unknown. In this study, we investigated the effect of varying doses of GGQLD on the total amount and distribution of gut bacteria in rats fed a high‐fat diet (HFD) for 8 weeks. Our analysis indicates that Oscillibacter and Ruminococcaceae_g_unclassified are the dominant families in the HFD group. Further, HFD‐dependent differences at the phylum, class, and genus levels appear to lead to dysbiosis, characterized by an increase in the Firmicutes/Bacteroidetes ratio and a dramatic increase in the Oscillibacter genus compared to the control group. Treatment with GGQLD, especially the GGQLL dose, improved these HFD‐induced changes in intestinal flora, leading to increased levels of Firmicutes, Clostridia, Lactobacillus, bacilli, and Erysipelotrichales that were similar to the controls. Taken together, our data highlight the efficacy of GGQLD in treating NAFLD and support its clinical use as a treatment for NAFLD/NASH patients.